The liver organoid microarray platform is constructed using induced pluripotent stem cells (iPSCs) and the patient’s own immune cells, creating a fully functional human liver environment that can mimic real-world patient responses to medications. This innovative model aims to address a notable gap in current drug testing methodologies, which often fail to replicate the intricacies of individual immune responses that lead to rare but severe liver injuries following drug administration. The research team’s co-first author, Fadoua El Abdellaoui Soussi, emphasizes the importance of capturing the interplay between liver cells and immune responses, which was previously obscured in traditional lab tests.

The unprecedented ability of this platform to incorporate autologous CD8⁺ T cells—critical immune cells that play a vital role in tissue health and recovery—marks a significant advance in preclinical toxicology. Standard animal models and traditional lab tests are ill-equipped to accurately forecast how specific genetic and immune profiles can affect drug tolerance. This new model aims to comprehensively assess how distinct patient populations, each with their own unique biology, might respond to various pharmaceuticals, thus paving the way for more personalized medicine.

In a compelling demonstration of the platform’s capabilities, the research team successfully replicated a known instance of immune-mediated liver injury resulting from the antibiotic flucloxacillin. This specific reaction is genetically linked to carriers of the HLA-B*57:01 risk gene, underscoring how critically the new organoid system can mimic the physiological processes occurring in susceptible patients. The model closely mirrored the clinical manifestations of immune-mediated toxicity, including the activation of T cells, the secretion of pro-inflammatory cytokines, and damage to hepatocytes, effectively bringing the predictive power of this model to the forefront.

This suite of capabilities is an outcome of extensive foundational work led by Takanori Takebe, a co-author on the study, who has pioneered methodologies for producing reliable human liver organoids from iPSCs. By reconfiguring these methodologies into a scalable microarray format and accommodating patient-specific immune cells, the CuSTOM Accelerator team has created a highly versatile tool that possesses the potential to transform drug testing protocols across the industry.

A major facet of this advancement is the partnership with Roche, a collaboration that embodies the intersection of academic research and industry application. Roche’s expertise in translational toxicology has been instrumental in refining and validating this new platform, demonstrating how synergistic relationships between academic institutions and pharmaceutical companies can yield significant health advancements. Adrian Roth, a prominent scientific director at Roche, succinctly articulates this collaboration’s potential, suggesting that it epitomizes the fusion of innovative academic ideas with practical industry insight.

As Cincinnati Children’s Hospital has been at the forefront of organoid research since the inception of functional human intestinal organoids in 2010, this latest endeavor showcases the institution’s ongoing commitment to advancing organoid medicine. Under the leadership of Dr. Magdalena Kasendra, director of research and development at CuSTOM, the focus has now expanded to developing tools that make these scientific advances actionable in clinical settings, prioritizing patient safety and effective drug development.

Looking ahead, the CuSTOM Accelerator’s objectives include automating organoid assays to facilitate high-throughput screening, a necessary evolution that will enable researchers to explore vast genetic diversity among donor populations. The ability to undertake such expansive screenings will enhance understanding of how drug efficacy and safety can vary greatly among different individuals, ensuring a more thorough consideration of human variability in therapeutic development.

Ongoing collaboration efforts, especially with technology companies like Molecular Devices and Danaher, signal a proactive approach in refining these organoid systems. By integrating automation and high-throughput technology, the research team aims to further bolster the predictive capabilities of their models, thus enhancing the rigor of preclinical safety assessments and ultimately expediting the journey from drug ideation to clinical application.

This innovative research represents just the beginning of a paradigm shift in the realm of drug safety testing. By bridging the realms of biology, engineering, and clinical insights, the vision of CuSTOM to transform organoid science into functional tools for health improvement is within reach. Researchers remain committed to developing solutions that could one day predict individual responses to therapies even before those treatments are introduced into clinical settings.

Through this advancement, Cincinnati Children’s Hospital continues to set the stage for pioneering work in personalized medicine, demonstrating how bespoke models can inform treatment decisions and protect patients from adverse drug reactions. As research progresses, the potential for this organoid technology to become a staple in medical testing and drug development grows, reinforcing the importance of tailored approaches to healthcare.

The road ahead is filled with promise, with the organoid platform poised to enhance our understanding of complex biological responses and ultimately improve patient outcomes in drug therapy. By continuing to innovate and adapt, the scientific community builds a strong foundation for future advancements in organoid medicine and its application in human healthcare.

Subject of Research: Lab-produced tissue samples
Article Title: Autologous Organoid-T Cell Co-Culture Platform for Modeling of Immune-Mediated Drug-Induced Liver Injury
News Publication Date: 26-Sep-2025
Web References: https://pubmed.ncbi.nlm.nih.gov/41001778/
References: Cincinnati Children’s Hospital Medical Center; Advanced Science
Image Credits: Cincinnati Children’s Hospital Medical Center

Keywords

Health and medicine, Biomedical engineering, Pharmaceuticals

At the core of this innovation lies San Pham, a tenacious doctoral candidate at Emory whose strategic approach and deep dive into chemical literature revitalized a reaction once considered frustratingly inconsistent and limited in scope. Her pioneering modifications to the catalytic system have transformed the Chan-Evans-Lam reaction from a capricious process with unpredictable yields into a robust, high-yielding synthesis platform. By refining catalyst activation and regeneration steps, Pham achieved yields of approximately 80 percent, compared to the suboptimal 20-50 percent reported in earlier attempts, thereby overcoming historical bottlenecks that restricted the reaction’s broader application.

The significance of synthesizing vinylic ethers resides in their unique structure: an oxygen atom bonded directly to a vinyl carbon, which is itself attached to an alkene moiety. These features render vinylic ethers indispensable intermediates in the laboratory synthesis of numerous natural products and pharmacologically relevant molecules, including plasmalogens—a class of ether phospholipids integral to cellular membranes with roles in antioxidation and anti-inflammatory processes. However, traditional synthetic routes to these ethers, especially those bearing complex alkene substituents, have been notoriously inefficient and limited.

For nearly six years, the McDonald laboratory at Emory, with Professor Frank McDonald at the helm, sought to develop a more practical synthetic methodology. While the Chan-Evans-Lam reaction, established over two decades ago, proved effective with simple substrates, its application to structurally sophisticated partners remained an unresolved challenge. The copper acetate catalyst essential to this reaction prone to exist as a dimeric complex, which hinders the catalytic activity necessary for successful coupling reactions involving complex molecules. This dimerization presented a critical obstacle, limiting the reaction’s reliability and reproducibility, factors crucial for scalable pharmaceutical synthesis.

Pham’s breakthrough came through her extensive examination of secondary literature, uncovering insights on ligand chemistry that allowed for the dissociation of the inert dimeric copper species into catalytically active monomers. She systematically evaluated numerous catalyst activators, commonly known as ligands, to stabilize the copper monomers, thereby enhancing catalytic turnovers. Although initial attempts raised the yield only moderately, the true leap forward emerged through her investigation into catalyst regeneration methods.

Identifying the slow regeneration of the copper catalyst as a production bottleneck, Pham innovated by substituting molecular oxygen—commonly used for catalyst turnover—with organic peroxides as more effective reoxidants. This clever substitution accelerated the catalyst’s regeneration cycle, suppressed undesirable side reactions, and shifted the reaction equilibrium towards the formation of desired vinylic ether products. This discovery not only boosted the yield but also increased reaction consistency, fostering reproducibility critical for application in industrial settings.

Pham’s refined protocol demonstrated impressive generality across a diverse array of substrates, expanding the usable chemical space for functionalized vinylic ethers. Her team successfully synthesized at least 15 previously unreported compounds, all yielding synthetically useful quantities. These newly accessible molecules offer promising scaffolds for the exploration of therapeutic agents, especially in fields requiring precise manipulation of bioactive lipid derivatives like plasmalogens.

The broader implications of this work resonate across medicinal chemistry and pharmaceutical research. Reliable access to functionalized vinylic ethers catalyzes the design and synthesis of complex molecular architectures that are often core components of drug candidates. By alleviating longstanding synthetic barriers, the improved Chan-Evans-Lam protocol empowers researchers to explore new chemical landscapes, potentially accelerating drug discovery pipelines for treatments of diseases linked to oxidative stress and inflammation.

Furthermore, the affordability and safety profile of the new reagents and catalysts bolster the reaction’s attractiveness for widespread laboratory adoption. The use of inexpensive copper catalysts paired with accessible ligands and organic peroxide oxidants reflects an economically viable and environmentally considerate approach, aligning with the growing emphasis on green chemistry principles in pharmaceutical manufacturing.

Looking beyond the immediate synthetic achievements, the McDonald laboratory aims to harness these advancements in the synthesis of plasmalogen analogs, probing their biological roles and therapeutic potential. Given plasmalogens’ implication in protecting cells from oxidative damage and modulating inflammation, this chemistry offers a vital tool for biochemists and pharmacologists seeking to develop novel interventions targeting metabolic and degenerative diseases.

Reflecting on the research journey, Pham emphasizes the value of perseverance and strategic hypothesis-driven experimentation in overcoming scientific challenges. Her methodical literature review coupled with targeted reaction design exemplifies a rational approach often overshadowed by random trial-and-error techniques in synthetic chemistry. This mindset not only yielded practical benefits but also embodies a reproducible pathway for future researchers facing comparable obstacles in complex reaction systems.

Professor McDonald highlights that this refined methodology not only advances Emory University’s research agenda but also holds promise for the scientific community at large. By providing detailed mechanistic insights and experimentally validated protocols, this work lays the foundation for further innovations in copper-catalyzed cross-coupling reactions, broadening the synthetic toolbox available for crafting biologically and pharmaceutically relevant molecules.

In essence, the evolution of the Chan-Evans-Lam reaction reported here transcends a mere technical improvement; it represents a conceptual leap that integrates catalyst activation, turnover, and regeneration into a cohesive, efficient system. This synergy enables the synthesis of structurally complex vinylic ethers previously deemed impractical, heralding a new era in organic synthesis that bridges methodological rigor with practical utility in drug discovery.

Subject of Research: Not applicable

Article Title: Chan-Evans-Lam Cu(II)-Catalyzed C-O Cross-Couplings: Broadening Synthetic Access to Functionalized Vinylic Ethers

News Publication Date: 27-Jun-2025

Web References: 10.1021/acs.orglett.5c01966

Keywords: Organic synthesis, Organic reactions, Chemical compounds, Pharmacology, Bioactive compounds

Indoles, characterized by a fused architecture of a benzene ring and a nitrogen-containing five-membered ring, serve as a foundational scaffold in many natural products and drugs. Their chemical versatility stems from the ability to selectively functionalize different ring positions, unlocking diverse synthetic pathways to tailor biologically relevant molecules. Among these positions, the C5 carbon has remained notably difficult to modify due to its inherent low reactivity and steric environment, limiting chemists’ capacity to explore a full range of chemical modifications there.

The research team, led by Associate Professor Shingo Harada, leveraged the unique reactivity of carbenes—highly reactive species featuring divalent carbon atoms—to accomplish a direct, regioselective C5–H alkylation of indoles. Transition metal catalysis, particularly involving copper in concert with silver salts, proved critical to enhancing activity and selectivity, maneuvering the reaction pathway to favor C5 functionalization. This method sidesteps the need for expensive rhodium catalysts used in prior approaches, making it not only more economically feasible but also more scalable for pharmaceutical synthesis.

The essence of this technique lies in the deployment of α-diazomalonates as carbene precursors in the presence of a mixed copper-silver catalyst system. Using N-benzyl indole derivatives equipped with electrophilic substituents such as enones or benzoyl groups at the 3-position, the reaction delivers alkylated products at C5 with high selectivity and impressive yields reaching up to 91%. Adjustment of reaction parameters—solvent concentration, catalyst loading, and substrate design—further optimized these outcomes, highlighting the robustness and broad substrate scope of the method.

Delving into the reaction mechanism through quantum chemical modeling, the researchers revealed a fascinating two-step process. Initially, the carbene species attaches transiently at the adjacent C4 position, forming a high-energy, strained three-membered ring intermediate. This intermediate subsequently undergoes a facile rearrangement, effectively migrating the new carbon–carbon bond to the coveted C5 position. The copper catalyst stabilizes both the initial intermediate and transition state, drastically lowering the activation energy barrier and enabling the otherwise unlikely rearrangement to proceed efficiently.

This intricate understanding of the mechanistic underpinnings not only validates the empirical approach but also paves the way for future innovations in transition-metal catalyzed C–H functionalization chemistry. The ability to selectively target the C5 position unlocks new synthetic routes to indole derivatives that closely resemble bioactive natural products and pharmaceutical candidates, thus expanding chemists’ ability to craft molecules with desired biological activities.

Indoles occupy a central role in drug development, evident from the approval of multiple indole-based therapeutics by the U.S. Food and Drug Administration over recent years. Applications span migraine treatment, antimicrobial therapy, and cardiovascular disease management, underlining their pharmacological significance. However, accessing selectively modified indole derivatives remains a bottleneck. The copper-catalyzed C5 alkylation addresses this bottleneck by offering a straightforward, reliable, and cost-effective strategy to generate highly functionalized indole frameworks.

The scalability of this copper catalyst system is particularly notable. By replacing expensive and rare rhodium catalysts with more abundant copper salts, the method advances sustainable chemistry principles while maintaining exceptional regioselectivity and yield. This transition is vital for the pharmaceutical industry to meet increasing demands for efficient and green synthetic methodologies that can be practically implemented in large-scale drug manufacturing.

Moreover, the method exhibits remarkable tolerance to diverse substituents on the indole ring. Substituted benzyl, methoxybenzyl, allyl, and phenyl groups are all compatible, thus affording access to a wide array of structurally varied indole derivatives. Such versatility is instrumental in medicinal chemistry, where subtle changes in molecular structure can radically affect biological activity and pharmacokinetics.

According to Dr. Harada, this breakthrough enhances the toolbox for chemists seeking to exploit indole scaffolds, noting that while the impact may not be seismic overnight, the steady accumulation of such advances fosters incremental progress vital for drug discovery. The team is actively pursuing further metal-carbene reaction systems to refine selectivity and efficiency, aspiring to develop synthetic strategies that could contribute to novel treatments for challenging diseases.

This research exemplifies the power of integrating mechanistic insights with innovative catalysis to overcome chemical challenges and streamline the synthesis of complex molecules. The combination of experimental optimization and theoretical modeling not only provides clarity on reaction pathways but also offers strategic avenues for developing analogous transformations in related heterocyclic systems.

In conclusion, the copper-catalyzed direct C5–H alkylation of indoles marks a significant step forward in the selective modification of these pharmacologically important molecules. By marrying economic catalyst choice with a deep understanding of reaction dynamics, this method equips medicinal chemists with a potent new strategy to generate diverse indole derivatives poised for therapeutic exploration. The promise of this approach—efficient, selective, and practical—heralds exciting possibilities in the synthesis of next-generation drugs.

Subject of Research:
Not applicable

Article Title:
Copper-catalyzed direct regioselective C5–H alkylation reactions of functionalized indoles with α-diazomalonates

News Publication Date:
15-Jul-2025

Web References:
https://doi.org/10.1039/D5SC03417E

References:
Harada S, Isono T, Yanagawa M, Nemoto T. Copper-catalyzed direct regioselective C5–H alkylation reactions of functionalized indoles with α-diazomalonates. Chemical Science. 2025 Jul 15.

Image Credits:
OLCF via Creative Commons Search Repository

Keywords

Indole chemistry, C5 functionalization, copper catalysis, carbene reactions, regioselective alkylation, α-diazomalonates, medicinal chemistry, synthetic methodology, drug discovery, transition metal catalysis, quantum chemical calculations, heterocyclic synthesis